Effect of MK-801 on endogenous dopamine release in vivo
- 1 September 1990
- journal article
- research article
- Published by Elsevier in Brain Research
- Vol. 528 (1) , 80-82
- https://doi.org/10.1016/0006-8993(90)90197-j
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- Ceruletide suppresses endogenous dopamine release via vagal afferent system, studied by in vivo intracerebral dialysisBrain Research, 1989
- Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving ratsNeuroscience, 1989
- Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activationJournal of Neuroscience, 1988
- Differential Control by N‐Methyl‐D‐Aspartate and Kainate of Striatal Dopamine Release In Vivo: A Trans‐Striatal Dialysis StudyJournal of Neurochemistry, 1988
- NMDA Receptors Trigger ExcitementScience, 1988
- Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbilJournal of Neuroscience, 1987
- In vivo presynaptic control of dopamine release in the cat caudate nucleus—II. Facilitatory or inhibitory influence ofl-glutamateNeuroscience, 1986
- Central sympathomimetic activity of (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo [a, d]cyclohepten‐5,10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic propertiesDrug Development Research, 1982
- The effects of phencyclidine on the uptake of 3H-catecholamines by rat striatal and hypothalamic synaptosomesLife Sciences, 1976